BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: Jun 27, 2025 · CIK: 882796
Sentiment: neutral
Topics: 8-K, filing, financial-disclosure
Related Tickers: BCRX
TL;DR
BioCryst filed an 8-K on 6/27/25, likely with financial updates or other material news.
AI Summary
On June 27, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided text excerpt.
Why It Matters
This 8-K filing signals that BioCryst Pharmaceuticals has made a significant disclosure to the SEC, which could contain important updates for investors regarding financial performance or material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, and the provided text does not contain information indicating significant risk.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- June 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for BioCryst Pharmaceuticals?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating disclosures related to the company's financial status and significant occurrences.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 27, 2025.
In which state is BioCryst Pharmaceuticals incorporated?
BioCryst Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for BioCryst Pharmaceuticals?
The principal executive office is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the SEC Act under which this 8-K is filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).